HLB Life Science Co., Ltd. (KOSDAQ:067630)

South Korea flag South Korea · Delayed Price · Currency is KRW
4,135.00
+120.00 (2.99%)
Apr 10, 2026, 3:30 PM KST
Market Cap503.84B -56.3%
Revenue (ttm)45.75B +39.6%
Net Income-99.79B
EPS-819.00
Shares Out121.85M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume330,312
Average Volume310,419
Open4,015.00
Previous Close4,015.00
Day's Range3,970.00 - 4,150.00
52-Week Range3,105.00 - 6,690.00
Beta-0.01
RSI58.74
Earnings DateMay 14, 2026

About HLB Life Science

HLB Life Science Co., Ltd. develops and manufactures in vitro diagnostic medical devices and quasi-drugs in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colon cancer, hepatocellular carcinoma, non-small cell lung cancer, breast cancer, mesothelioma, renal cell carcinoma, and neuroendocrine tumors; and Pyrotinib, an anticancer drug that inhibits the proliferation, division, and survival of cancer cells. In addition, the co... [Read more]

Sector Utilities
Founded 1998
Employees 153
Stock Exchange KOSDAQ
Ticker Symbol 067630
Full Company Profile

Financial Performance

Financial Statements